Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 May 2017 07:00

RNS Number : 6026F
Scancell Holdings Plc
19 May 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Scancell Holdings PLC

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc

Legal & General (Unit Trust Managers) Limited (UTM)

Legal & General Investment Management Limited (LGIM)

4. Full name of shareholder(s)  (if different from 3.):

n/a

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

16 May 2017

6. Date on which issuer notified:

18 May 2017

7. Threshold(s) that is/are crossed orreached:

 

 

 

LGIM (Above 5%) UTM (Above 5%)

 

 

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD GBP0.001

 

(LGIM)

 

First notification under DTR Sourcebook

 

 16,000,000

-

16,000,000

-

5.13%

ORD GBP0.001

 

(UTM)

 

First notification under DTR Sourcebook

16,000,000

-

16,000,000

-

5.13%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 16,000,000

 

LGIM

 

5.13%

 

 16,000,000

 

UTM

 

5.13%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 16,000,000 -5.13% = Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 16,000,000 - 5.13% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 16,000,000 - 5.13% = Total Position)

Legal & General (Unit Trust Managers) Limited ( 16,000,000 - 5.13% = UTM)

Legal & General Group Plc (Direct) (L&G)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance (Pensions Management) Limited (PMC)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  312,058,098

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFFREVITLID
Date   Source Headline
12th Sep 20193:56 pmRNSResult of AGM
4th Sep 20197:00 amRNSFirst Collaboration Agreement for AvidiMab
20th Aug 20192:23 pmRNSNotice of AGM
20th Aug 20197:00 amRNSFinal Results for the year ended 30 April 2019
19th Aug 20197:00 amRNSUpdate on the SCIB1 Phase 2 clinical trial
7th Aug 20197:00 amRNSNotice of Final Results
1st Jul 20197:00 amRNSH1 2019 Business Update
18th Jun 20199:16 amRNSHolding(s) in Company
18th Jun 20197:00 amRNSBoard Appointment
17th Jun 201910:45 amRNSHolding(s) in Company
14th Jun 20194:41 pmRNSSecond Price Monitoring Extn
14th Jun 20194:35 pmRNSPrice Monitoring Extension
13th Jun 20197:00 amRNSShare Subscription and Issue of Equity to Vulpes
29th May 201911:05 amRNSSecond Price Monitoring Extn
29th May 201911:00 amRNSPrice Monitoring Extension
20th May 20197:00 amRNSScancell and CRUK provide an update on SCIB2
10th May 20197:00 amRNSClinical Advisory Board and Update on Modi-1
25th Apr 20197:00 amRNSUK approval to start SCIB1 Phase 2 trial
8th Apr 20197:00 amRNSJapan patent for Moditope immunotherapy platform
21st Mar 20197:00 amRNSProfessor Lindy Durrant receives Waldenström award
20th Mar 20197:00 amRNSScancell strengthens IP portfolio
5th Mar 20196:27 pmRNSHolding(s) in Company
4th Mar 20194:40 pmRNSSecond Price Monitoring Extn
4th Mar 20194:35 pmRNSPrice Monitoring Extension
21st Feb 20197:00 amRNSChange of Auditor
31st Jan 20197:00 amRNSInterim Results
23rd Jan 20197:00 amRNSUpdate on Cancer Research UK's Grand Challenge
21st Jan 20197:00 amRNSAppoints Heads of Research and Manufacturing
12th Nov 20187:00 amRNSScancell to Present at Two Conferences
1st Nov 20187:00 amRNSScancell to present at Proactive Investors Forum
30th Oct 20185:18 pmRNSResults of AGM
30th Oct 20187:00 amRNSIdentification of 2nd Moditope Cancer Vaccine
24th Oct 20189:05 amRNSSecond Price Monitoring Extn
24th Oct 20189:00 amRNSPrice Monitoring Extension
24th Oct 20187:00 amRNSUpdate on SCIB1 Phase 2 Clinical Study
5th Oct 20187:00 amRNSNotice of AGM
25th Sep 20187:00 amRNSFinal Results for the year ended 30 April 2018
18th Sep 20187:00 amRNSNotice of Final Results
10th Aug 20187:00 amRNSBoard Change
9th Aug 20187:00 amRNSAgreement
25th Jul 20182:45 pmRNSDirector/PDMR Shareholding
24th Jul 20187:00 amRNSIssue of Equity
18th Jul 20187:00 amRNSScancell exercises TriGrid commercial option
23rd May 20187:00 amRNSGrant of European patent for Moditope platform
11th May 20181:11 pmRNSHolding(s) in Company
9th May 201810:12 amRNSHolding(s) in Company
8th May 20187:00 amRNSResult of the Open Offer and PDMR Shareholdings
23rd Apr 201812:43 pmRNSHolding(s) in Company
20th Apr 20184:32 pmRNSHolding(s) in Company
18th Apr 20182:29 pmRNSResult of Placing and Subscription and PDMR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.